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Pulmonary arterial hypertension (PAH) is a rare and devastating dis-
ease characterized by progressive increases in pulmonary arterial 
pressure and pulmonary vascular resistance which eventually leads to 
right ventricular failure and death. Early thought process was that exer-
cise and increased physical activity may be detrimental to PAH patients 
however many small cohort trials have proven otherwise. In addition to 
the many pharmaceutical options, exercise and pulmonary rehabilita-
tion have also been shown to increase exercise capacity as well as 
various aspects of psychosomatic health. As pulmonary and exercise 
rehabilitation become more widely used as an adjuvant therapy patient 
outcomes improve and physicians should consider this in the therapeu-
tic algorithm along with pharmacotherapy. 
Keywords: Pulmonary arterial hypertension, Pulmonary rehabilitation, 
Six minute walk test, Exercise intolerance, Pulmonary hypertension, 
Health related quality of life
INTRODUCTION
Pulmonary hypertension is a rare and devastating disease char-
acterized by progressive increases in pulmonary arterial pressure 
and pulmonary vascular resistance which eventually leads to right 
ventricular failure and death (Badesch et al., 2009; Farber and Lo-
scalzo, 2004). It may due to various etiologies such as left heart 
disease, parenchymal lung disease, chronic thromboembolic dis-
ease, hematologic disorders or it may be idiopathic in nature (Ta-
ble 1) (Simonneau et al., 2013) though the clinical picture of these 
patients is similar. Patients with all forms of pulmonary hyperten-
sion present with progressive dyspnea and increasing exercise in-
tolerance. More specifically WHO Group I pulmonary arterial 
hypertension (PAH) is due to direct injury to the pulmonary ves-
sels and vascular bed. At present there is no cure for PAH, howev-
er over the past decade targeted pharmaceutical options have be-
come available. In addition to these pharmaceutical options, exer-
cise and pulmonary rehabilitation have also been shown to in-
crease exercise capacity, WHO functional class, peak oxygen con-
sumption and resting heart rate (Grunig et al., 2011; 2012a). It 
has also been seen that exercise may improve health related quali-
ty of life (HRQoL) (Chan et al., 2013), depression (Verma et al., 
2014) and fatigue (Talwar et al., 2014). It is imperative that clini-
cians use pulmonary rehabilitation and exercise as an adjuvant 
therapy in the treatment of these patients as its benefits are clearly 
evident. This review will attempt to emphasize the importance of 
structured exercise training in the pulmonary hypertension popu-
lation despite etiology and disease severity. 
PULMONARY REHABILITATION
Over the last few decades pulmonary rehabilitation has ad-
vanced as a therapeutic option in patients of chronic respiratory 
disease. Evidence based medicine has determined that pulmonary 
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rehabilitation can reduce dyspnea, increase exercise tolerance and 
improve health related quality of life in all settings of chronic re-
spiratory disease (Spruit et al., 2013). Pulmonary rehabilitation is 
defined as a comprehensive intervention based on a thorough pa-
tient assessment followed by patient-tailored therapies, which in-
clude, but are not limited to, exercise training, education, and be-
havior change, designed to improve the physical and psychologi-
cal condition of people with chronic respiratory disease and to 
promote the long-term adherence of health-enhancing behaviors 
(Spruit et al., 2013).
Use of exercise training and pulmonary rehabilitation in cardio-
pulmonary diseases such as congestive heart failure (CHF) and 
chronic obstructive pulmonary disease (COPD) have shown pa-
tient outcome improvement and are well described (Hambrecht 
et al., 1998; Ries et al., 2007). However, in the setting of pulmo-
nary hypertension only small cohorts of studies exist. The use of 
exercise training and pulmonary rehabilitation in a pulmonary 
hypertension population is still underutilized though studies have 
shown its beneficial effect (de Man et al., 2009; Martinez-Quin-
tana et al., 2010). 
PULMONARY ARTERIAL HYPERTENSION 
AND EXERCISE IMPAIRMENT
Pulmonary arterial hypertension is characterized by a progres-
sive increase in pulmonary vascular resistance, leading to right 
ventricular failure and eventual death (Simonneau et al., 2013). 
Prior to pharmacological intervention traditional therapies were 
utilized which included anticoagulants, diuretics, and supplemen-
tal oxygen. However, after the pathophysiologic process became 
well known disease-targeted therapies such as phosphodiesterase 
inhibitors, endothelin receptor antagonists and prostacyclins have 
become more widely used (Rubin, 2013). Combinations of these 
agents are used to decrease pulmonary vascular resistance, decrease 
pulmonary artery pressures and increase exercise tolerance (Pugh 
et al., 2013). Combination therapy with disease specific drugs has 
shown symptomatic relief as well as been shown to increase exer-
cise capacity and possibly survival rate in pulmonary hypertension 
(Ghofrani et al., 2002; Hoeper et al., 2004). Though these medi-
cations address quantitative measures of pulmonary vasculature 
and hemodynamics, exercise capacity and quality of life continue 
to decline despite optimized treatment. 
Table 1. World Health Organization's classification of pulmonary hypertension (Simonneau et al., 2013)
Group I - Pulmonary Arterial hypertension (PAH) 
  Idiopathic PAH
  Heritable PAH (BMPR2, ALK1, ENG, SMAD9, CAV1, KCNK3, Unknown)
  Drug and toxin induced   
  Associated with (i) Connective tissue disease, (ii) HIV infection, (iii) Portal hypertension, (iv) Congenital heart disease, (v) Schistosomiasis
  Pulmonary veno-occlusive disease and/ or pulmonary capillary hemangiomatosis
  Persistent pulmonary hypertension of the newborn 
Group II - Pulmonary hypertension due to left heart disease
  Left ventricular systolic dysfunction
  Left ventricular diastolic dysfunction
  Valvular disease
  Congenital/ acquired left heart inflow/ outflow tract obstruction and congenital cardiomyopathies
Group III - Pulmonary hypertension due to lung diseases and/or hypoxia 
  Chronic obstructive pulmonary disease 
  Interstitial lung disease 
  Other pulmonary diseases with mixed restrictive and obstructive pattern
  Sleep-disordered breathing 
  Alveolar hypoventilation disorders 
  Chronic exposure to high altitudes 
  Developmental lung disease 
Group IV - Chronic thromboembolic pulmonary hypertension (CTEPH) 
Group V - Pulmonary hypertension with unclear multifactorial mechanisms
  Hematologic disorders: chronic hemolytic anemia, myeloproliferative disorders, splenectomy
  Systemic disorders: sarcoidosis, pulmonary histiocytosis, lymphangioleimyomatosis
  Metabolic disorders: glycogen storage disease, Gaucher’s disease, hypothyroidism 
  Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure, segmental pulmonary hypertension
5th World Symposium on Pulmonary Hypertension, Nice, France 2013. BMPR, Bone Morphogenic Protein Receptor Type II; CAV1, Caveolin-1; ENG, Endoglin; HIV, Human Im-
munodeficiency Virus.
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Exercise capacity is reduced in the setting of pulmonary hyper-
tension which is associated with depression and anxiety disorders 
as demonstrated by Lowe et al. (2004). Until a better understand-
ing of exercise training in the setting of pulmonary hypertension 
was established the early thought process was that exercise and in-
creased physical activity may be detrimental to these patients and 
may actually increase pulmonary pressures expediting the prolif-
erative process (Badesch et al., 2004). 
The pathogenesis of pulmonary hypertension is multifactorial. 
WHO group I pulmonary hypertension, also referred to as pul-
monary arterial hypertension is characterized by abnormalities ini-
tiating in the small arteries of the pulmonary vasculature, includ-
ing enhanced cell proliferation and reduced apoptosis, endothelial 
dysfunction, thrombosis in situ, inflammation, and plexiform arte-
riopathy, leading to vascular remodeling and excessive vasocon-
striction (McLaughlin et al., 2009). This may due to connective 
tissue diseases, congenital heart disease, HIV infection, portal hy-
pertension, heritable or it may be idiopathic in nature. In the set-
ting of PAH these changes cause resistance for the blood flowing 
through the pulmonary arteries. This leads to increased pulmo-
nary artery pressures and increased pulmonary vascular resistance 
pressures eventually leading to right heart failure due to increased 
after load, decreased contractility, and reduced cardiac output 
(Waxman, 2012). The combination of reduced cardiac output and 
increased pulmonary vascular resistance creates a situation where 
exertion causes dyspnea and negatively affects quality of life. 
Exertional dyspnea being a common symptom across the pul-
monary hypertension population provides a method to assess dis-
ease severity and progress. Dyspnea may be measures subjectively 
by using instruments such as the Borg Dyspnea Scale and Medical 
Research Council Dyspnea Scale (Bestall et al., 1999; Borg, 1970). 
The severity of exertion is helpful to assess severity and prognosis 
in pulmonary hypertension. The 6-min walk test and the measure 
distance is used to assess exercise capacity in patients diagnosed 
with pulmonary disease and is used as the determinant and pri-
mary endpoint in many exercise training clinical trials (ATS Com-
mittee on Proficiency Standards for Clinical Pulmonary Function 
Laboratories, 2002). Exercise tolerance can also be measured using 
cardiopulmonary exercise testing (American Thoracic, Society/
American College of Chest Physicians, 2003). 
CLINICAL TRIALS OF EXERCISE TRAINING 
AND PULMONARY REHABILITATION
Though early thought process advised against increased exer-
tion and exercise a change in thinking brought upon clinical trials 
of exercise respiratory training in the pulmonary hypertension 
population (Table 2). In Mereles et al., (2006) conducted the first 
prospective randomized study to evaluate the effects of exercise on 
chronically ill pulmonary hypertension patients, stable on medi-
cation. Thirty patients with either pulmonary arterial hyperten-
sion or chronic thromboembolic pulmonary hypertension were 
randomly assigned to either a control or training group. Primary 
end points were the change in 6-min walk distance from baseline 
to week 15 in the scores of the Short Form Health Survey quali-
ty-of-life questionnaire (SF-36). Secondary endpoints were also as-
sessed. At week 15, patients in the primary and secondary train-
ing groups had an improved 6-min walking distance. Exercise 
training was shown to be well tolerated and improved scores of 
quality of life, WHO functional class and peak oxygen consump-
tion. Systolic pulmonary artery pressure values at rest did not 
change significantly after 15 weeks of exercise and respiratory 
training (Mereles et al., 2006).
Though the ground work for exercise training in pulmonary hy-
pertension was laid out, furthering testing was required. De Man et 
al. (2009) conducted a trial of exercise on only patients with WHO 
Group I PAH. Nineteen clinically stable PAH patients with mod-
erate disease underwent exercise training program for 12 weeks in 
which maximal capacity endurance capacity and quadriceps func-
tion were assessed and serial quadriceps muscle biopsies were ob-
tained. 6-min walk distance and peak exercise capacity did not 
change after training. However, endurance capacity improved sig-
nificantly after training. Training also enhanced aerobic capacity of 
the quadriceps, by increasing capillarization (de Man et al., 2009). 
A study by Fox et al. (2011) of 22 PAH or CTEPH patients 
demonstrated significant increase in 6 MWD as well as Peak VO2. 
The rehabilitation program consisted of 24 1-h sessions of exercise 
training/rehabilitation over the course of 12 weeks. Peak work rate 
during cardiopulmonary exercise test also increased in the rehabili-
tation group with borderline significance. Echocardiography and 
blood N-terminal pro-brain natriuretic peptide levels were un-
changed. No adverse events occurred due to the rehabilitation pro-
gram demonstrating safety.
With evidence of the positive benefits of exercise training in the 
setting of pulmonary hypertension further clinical trials were con-
ducted. Grunig et al. (2011) demonstrated the benefits of exercise 
training in a connective tissue disease population with pulmonary 
hypertension (Grunig et al., 2012b). Patients with RHC con-
firmed connective tissue disease related pulmonary hypertension 
received in-hospital exercise training for 3 weeks which was con-
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tinued for another 12 weeks at home. Patients improved the mean 
distance walked in 6 min, resting heart rate, peak oxygen con-
sumption, and oxygen saturation. In addition systolic pulmonary 
artery pressure, and diastolic systemic blood pressure improved 
significantly after 3 weeks of exercise training. The 1- and 2-yr 
overall-survival rates were found to be 100%, the 3-yr survival rate 
73% (Grunig et al., 2012a). 
Another study by Grunig et al. (2011) aimed to assess disease 
progression and survival in patients with severe chronic pulmo-
nary hypertension. Fifty eight patients with severe pulmonary hy-
pertension on stable medication received exercise and respiratory 
training in hospital for 3 weeks which was later continued at 
home. They were prospectively followed for 24±12 months. Pri-
mary endpoints were time to clinical worsening and survival. Ad-
verse events and changes in the 6-min walking test, QoL, WHO 
functional class and gas exchange were secondary endpoints and 
were evaluated at baseline and at weeks 3 and 15. The results 
showed that all patients tolerated the exercise training well with-
out any severe adverse events. In week 15, 6-min walking test re-
sults were significantly improved compared to baseline as well as 
quality of life scores, WHO functional class, peak oxygen con-
sumption, heart rate at rest and maximal workload. Survival at 1 
and 2 yr was 100 and 95%, respectively (Grunig et al., 2011). 
Fifteen events occurred during the follow-up. It was concluded 
that exercise and respiratory training as add-on to medical treat-
ment may improve exercise capacity and QoL, with a good long 
term safety profile.
NON PHYSICAL EFFECTS OF EXERCISE 
AND PULMONARY REHABILITATION
As pulmonary hypertension’s most debilitating manifestation is 
exercise intolerance most trials focus on improvement in this char-
acteristic as well as hemodynamics. However, in addition to physi-
cal improvement, there is a great deal of improvement in aspects of 
psychosomatic domains. It is well known that patients with pul-
monary hypertension experience depression (Verma et al., 2014) 
and report increased levels of fatigue severity (Talwar et al., 2014). 
It is also well known that these patients have a severely impaired 
health related quality of life (Taichman et al., 2005). These aspects 
of psychosomatic medicine may also be addressed with the use of 
structured pulmonary rehabilitation and exercise programs in this 
population. A study by Kim et al. (2013) showed the effects that 
dyspnea has on depression and health related quality of life 
(HRQoL). Pulmonary rehabilitation programs have also showed 
improvement in fatigue severity as well as depression (Talwar et al., 
Table 2. Summary of exercise testing trial in the setting of pulmonary hypertension     
Study n Study Design Intervention Duration of Exercise/Rehab Program Results
Mereles et al., 2006 30 RCT Bicycle training, Walking, Dumbbell, 
Respiratory Training
3 week in hospital+
12 weeks at home
Improvement in 6MWD, QOL scores, 
WHO FC, VO2 (peak +AT) and workload. 
No change in SPAP; No SAE
De Man et al., 2009 19 Non-randomized 
single group
Bicycle Training, Quadriceps stretch 
and endurance
12 weeks in rehabilitation 
center
Stable 6MWD, peak exercise capacity. 
Increased muscle strength, capillaries in 
muscle, oxidative enzyme activity.
Chan et al., 2013 23 RCT Treadmill walking only for 30-45 min. 10 weeks 24-30 session in 
rehabilitation facility
Increase in 6MWD, QOL scores, Time to 
exercise intolerance, Peak work rate; No 
SAE
Fox et al., 2010 22 NRCT 1 hr. per session, aerobic interval 
training, bicycle, treadmill, walking, 
step climbing; resistance training. 
12 weeks in outpatient 
rehabilitation center
Increase in 6MWD, Peak VO2, Peak WR. 
BNP, SPAP and CO remained the same; 
No SAE
Grunig et al., 2011 58 NRCT single group Daily bicycle training, dumbbell 
training, respiratory training 
3 weeks in hospital, 
12 week at home
Increased 6MWD, QOL scores, WHO FC, 
Peak VO2, Maximum workload and 
decreased resting HR; No SAE
Grunig et al., 2012 183 NRCT single group Daily interval bicycle training, walking, 
dumbbell training, mental training, 
home
3 weeks in hospital, 
12 week at home
Increased 6MWD, QOL scores, WHO FC, 
Peak VO2; Decreased resting heart rate, and 
SPAP; No SAE
Grunig et al., 2012 21 NRCT single group Daily interval bicycle training, walking, 
dumbbell training, mental training, 
home training
3 weeks in hospital, 
12 week at home
Increased 6MWD, QOL scores, WHO FC, 
Peak VO2, Maximum workload increased O2 
SPAP; Survival at 2 yr-100%, 3 yr 73%
RCT, Randomized Controlled Trial; 6MWD, 6-min walk distance; QOL, Quality of life; WHO-FC, World Health Organization Functional Class; SAE, Serious Adverse Events; NRCT, 
Non-Randomized Control Trial; HR, Heart Rate; BNP, Brain Natruietric Peptide; SPAP, Systolic Pulmonary Artery Pressure.    
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2014) which provide evidence of further benefits of such programs. 
A more recent study by Chan et al. (2013) went ahead to deter-
mine the effects of intense treadmill exercise on cardio-respiratory 
function as well as quality of life in patients with pulmonary hy-
pertension. Patients were randomized to a 10-week disease specif-
ic education only group or education/exercise combined group. 
The exercise program consisted of 24-30 sessions of treadmill 
walking for 30-45 min per session. Outcome variables included 
changes in 6-min walk test (6 MWT) distance, time to exercise 
intolerance, peak work rate from a cardiopulmonary treadmill 
test, and quality-of-life measures, including the SF-36 and Cam-
bridge Pulmonary Hypertension Outcome Review (CAMPHOR) 
(Chan et al., 2013). The results following 10 weeks of interven-
tion, demonstrated an improvement in 6 MWT distance, in-
creased time to exercise intolerance, and peak WR. Additionally, 
the exercise group showed increased quality of life score according 
to the SF-36 as well as the CAMPHOR scale (Chan et al., 2013). 
CONCLUSIONS
Pharmacotherapy for pulmonary arterial hypertension has ad-
vanced over the past decade and has provided clinicians with a 
disease specific approach which has led to the improvement in 
prognosis of PAH patients. However, patients continue to experi-
ence significant exertional symptoms accompanied by reduced 
functional capacity and diminished health-related quality of life. 
From the trials that have been conducted, the evidence supports 
the benefits and safety of exercise training and rehabilitation pro-
grams in the pulmonary hypertension populations. Initial exercise 
training and pulmonary rehabilitation programs were assessed in 
a stable, treated, systolic heart failure, and COPD and showed im-
proved functional capacity and reduced exercise intolerance, 
symptoms of dyspnea, and fatigue.
Trials conducted in a pulmonary hypertension population 
showed improvement in exercise endurance and muscle strength 
as well as quality of life with the implementation of exercise train-
ing and cardiopulmonary rehabilitation as part of their medical 
care without a good safety profile. In conjunction with pharmaco-
therapy all patients with confirmed pulmonary arterial hyperten-
sion should be treated with a pulmonary rehabilitation and exer-
cise training program. 
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